Global /Norway /Healthcare /Biotechnology /BGBIO

BerGenBio ASA

BGBIO

• OSL: BGBIO • Delayed

1.17NOK 0%

0.1236 USD

As of 8 June 2026, BerGenBio ASA has a market cap of $4.89M USD, ranking #44577 globally and #245 in Norway. It ranks #3948 in the Healthcare sector, and #780 in the Biotechnology industry.

Global Rank

44577

Country Rank

245

Sector Rank

3948

Industry Rank

780

Key Stats

Market Cap

$4.89MUSD

45.73M NOK

Enterprise Value

-$2.51MUSD

-23.78M NOK

Revenue (TTM)

$578.37KUSD

5.41M NOK

EBITDA (TTM)

-$12.18MUSD

-115.28M NOK

Net Income (TTM)

-$11.51MUSD

-107.58M NOK

PS Ratio

8.5

PB Ratio

0.7

Company Profile

Country (HQ)

Norway

Sector

Healthcare

Industry

Biotechnology

CEO

Olav Hellebo open_in_new

Employees

Founded

2007

Website

bergenbio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	-4.1%	-7.3%	-11%	-39%	-86%	-87%	-99%	-100%

News

Markets

Exchange	Ticker	Price	Quotes
Euronext Oslo Børs (OSL) MIC: XOSL PRIMARY	BGBIO ISIN: NO0013251173 Shares Out.: Shares Outstanding: 39.087M¹ Shares Float: 25.575M² TV: TradingView: OSL: BGBIO SA: Stock Analysis: OSL: BGBIO YF: Yahoo Finance: BGBIO.OL GF: Google Finance: OSL: BGBIO BA: Barron's: BGBIO MS: Morningstar: XOSL: BGBIO	1.17 NOK	TV: TradingView: OSL: BGBIO SA: Stock Analysis: OSL: BGBIO YF: Yahoo Finance: BGBIO.OL GF: Google Finance: OSL: BGBIO BA: Barron's: BGBIO MS: Morningstar: XOSL: BGBIO

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About BerGenBio ASA

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory disease in Norway. It develops BGBIL025, a JAK2 inhibitor indicated, which is in Ph1b/2a for treatment of the bone marrow disorder myelofibrosis. The company was incorporated in 2007 and is based in Bergen, Norway.

Similar Companies

Industry: Biotechnology (Norway)

Name	Market Cap (USD) diff.	PE	Country
Circio Holding ASA OSL: CRNA	$231.81M 2.17B NOK 5K%	-	Norway
Zelluna ASA OSL: ZLNA	$66.06M 617.34M NOK 1K%	-	Norway
EXACT Therapeutics AS OSL: EXTX	$9.88M 92.36M NOK 102%	-	Norway

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 4M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 3M%	19.0	United States
argenx SE EBR: ARGX	$48.08B 41.39B EUR 982K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.48B 68.19T KRW 909K%	35.5	South Korea
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 879K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.72B 33.71B CHF 873K%	37.2	Switzerland

chevron_leftBack